Related Experiment Video
Updated: May 16, 2026
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
Molecular characterisation of cell line models for triple-negative breast cancers
Anita Grigoriadis1, Alan Mackay, Elodie Noel
1Breakthrough Breast Cancer Research Unit, Guy's Hospital, King's Health Partners AHSC, King's College London School of Medicine, London SE1 9RT, UK. Anita.grigoriadis@kcl.ac.uk
Background:
Triple-negative breast cancers (BC) represent a heterogeneous subtype of BCs, generally associated with an aggressive clinical course and where targeted therapies are currently limited. Target validation studies for all BC subtypes have largely employed established BC cell lines, which have proven to be effective tools for drug discovery.
Results:
Given the lines of evidence suggesting that BC cell lines are effective tools for drug discovery, we assessed the similarities between triple-negative BCs and cell lines, to identify in vitro representatives, modelling the diversity within this BC subtype. 25 BC cell lines, enriched for those lacking ER, PR and HER2 expression, were subjected to transcriptomic, genomic and epigenomic profiling analyses and comparisons were made to existing knowledge of corresponding perturbations in triple-negative BCs. Transcriptional analysis segregated ER-negative BC cell lines into three groups, displaying distinctive abundances for genes involved in epithelial-mesenchymal transition, apocrine and high-grade carcinomas. DNA copy number aberrations of triple-negative BCs were well represented in cell lines and genes with coordinately altered gene expression showed similar patterns in tumours and cell lines. Methylation events in triple-negative BCs were mostly retained in epigenomes of cell lines. Combined methylation and gene expression analyses revealed a subset of genes characteristic of the Claudin-low BC subtype, exhibiting epigenetic-regulated gene expression in BC cell lines and tumours, suggesting that methylation patterns are likely to underpin subtype-specificity.
Conclusion:
Here, we provide a comprehensive analysis of triple-negative BC features on several molecular levels in BC cell lines, thereby creating an in-depth resource to access the suitability of individual lines as experimental models for studying BC tumour biology, biomarkers and possible therapeutic targets in the context of preclinical target validation.
Insights
This study validates triple-negative breast cancer (BC) cell lines as models for drug discovery. Comprehensive molecular profiling reveals cell lines accurately represent BC subtype diversity and genetic alterations for preclinical research.
Area of Science:
- Oncology
- Genomics
- Molecular Biology
Background:
- Triple-negative breast cancer (TNBC) is aggressive with limited targeted therapies.
- Established breast cancer cell lines are crucial for drug discovery and target validation.
Purpose of the Study:
- To assess the molecular similarities between TNBC tumors and cell lines.
- To identify suitable in vitro models that represent the diversity of TNBC.
Main Methods:
- Transcriptomic, genomic, and epigenomic profiling of 25 breast cancer cell lines lacking ER, PR, and HER2 expression.
- Comparison of cell line data with existing knowledge of TNBC perturbations.
- Analysis of DNA copy number aberrations, gene expression, and methylation patterns.
Main Results:
- Transcriptional analysis classified ER-negative cell lines into three distinct groups based on gene expression.
- Cell lines effectively modeled DNA copy number aberrations and coordinated gene expression patterns found in TNBC tumors.
- Methylation events in TNBC were largely retained in cell lines, with combined analyses identifying Claudin-low subtype-specific genes.
Conclusions:
- This study provides a comprehensive molecular resource for evaluating TNBC cell line suitability as preclinical models.
- The findings support the use of these cell lines for studying TNBC biology, identifying biomarkers, and validating therapeutic targets.
